AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9591742 — intervention group
Group type: COMPARATOR
Intervention: High-oleic acid diet
Number of subjects: 15
Study 7839092 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple treatment consisting of bismuth subnitrate, oxytetracycline, and metronidazole for 14 days
Number of subjects: 74
Study 3279095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 30
Study 3279095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29768465 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated treatment (stopping antibiotics at Day 7)
Number of subjects: 54
Study 29768465 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment (continuing antibiotics until Day 14)
Number of subjects: 54
Study 29768465 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated treatment
Number of subjects: 54
Study 29768465 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment
Number of subjects: 54
Study 25932993 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 20
Study 25047457 — intervention group
Group type: EXPERIMENTAL
Intervention: PS post/cam tibial insert
Number of subjects: 111
Study 25047457 — intervention group
Group type: COMPARATOR
Intervention: CS anterior‐lipped tibial insert
Number of subjects: 111
Study 22640986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day)
Number of subjects: 19
Study 22640986 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10mg/day)
Number of subjects: 19
Study 20863930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 40
Study 20863930 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 40
Study 18826867 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methods for average bioequivalence evaluation including widening bioequivalence limits, scaling limits, and alternative bioavailability measures.
Number of subjects: 0
Study 18826867 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods to establish bioequivalence limits combined with alternative methods for constructing confidence intervals.
Number of subjects: 0
Study 16011671 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 45
Study 16011671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 45
Study 16011671 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 45
Study 16011671 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 45
Study 12385455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation procedure
Number of subjects: 122
Study 12385455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion identification/removal
Number of subjects: 122
Study 12385455 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic data
Number of subjects: 122
Study 12385455 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient history
Number of subjects: 122
Study 12385455 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure quality
Number of subjects: 122
Study 12385455 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure interpretation
Number of subjects: 122
Study 10437376 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 0
Study 8574510 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195, 50 mg
Number of subjects: 6
Study 8574510 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195, 100 mg
Number of subjects: 6
Study 8574510 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195, 250 mg
Number of subjects: 6
Study 8574510 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195, 500 mg
Number of subjects: 6
Study 8574510 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195, 1000 mg
Number of subjects: 6
Study 8574510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11527144 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of bisoprolol once daily (o.d., n = 20)
Number of subjects: 40
Study 11527144 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of nifedipine sustained release (SR) b.i.d. (n = 20)
Number of subjects: 40
Study 334688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 0
Study 334688 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 29168881 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure of a temporary ileostomy (at 8-13 days)
Number of subjects: 112
Study 29168881 — intervention group
Group type: COMPARATOR
Intervention: Late closure of a temporary ileostomy (at more than 12 weeks)
Number of subjects: 112
Study 27595692 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated hovering intervention based on behavioral economics concepts, implemented over 1 year.
Number of subjects: 1509
Study 27595692 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1509
Study 25044050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 23
Study 25044050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22914037 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocellulose dressing with polyhexanide (Group A)
Number of subjects: 60
Study 22914037 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic dressing with dialkyl-carbamoyl-chloride (Group B)
Number of subjects: 60
Study 20938333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pregabalin 150 mg/12 h
Number of subjects: 48
Study 20938333 — intervention group
Group type: COMPARATOR
Intervention: Prazepam 10 mg/12 h
Number of subjects: 48
Study 18269558 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) pacing
Number of subjects: 22
Study 18269558 — intervention group
Group type: COMPARATOR
Intervention: Biventricular (BIV) pacing
Number of subjects: 22
Study 16187778 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 53
Study 16187778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Abstinence
Number of subjects: 53
Study 12944569 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption for four months followed by a change in antiretroviral regimen
Number of subjects: 270
Study 12944569 — intervention group
Group type: COMPARATOR
Intervention: Immediate change in regimen (control group)
Number of subjects: 270
Study 12944569 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption
Number of subjects: 270
Study 12944569 — intervention group
Group type: COMPARATOR
Intervention: Structured treatment interruption and immediate change in regimen
Number of subjects: 270
Study 10658043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (Acz; 10 mg/kg body wt iv)
Number of subjects: 7
Study 10658043 — intervention group
Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 7
Study 9074366 — intervention group
Group type: EXPERIMENTAL
Intervention: Early necrosectomy (within 48 to 72 hours of onset)
Number of subjects: 36
Study 9074366 — intervention group
Group type: COMPARATOR
Intervention: Late necrosectomy (at least 12 days after onset)
Number of subjects: 36
Study 8436155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg orally three times a day
Number of subjects: 43
Study 8436155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (6 weeks)
Number of subjects: 39
Study 3094804 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 patients with low susceptibility)
Number of subjects: 39
Study 3094804 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients with low susceptibility)
Number of subjects: 39
Study 28898530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal electrothermal therapy (IDET)
Number of subjects: 122
Study 28898530 — intervention group
Group type: COMPARATOR
Intervention: Circumferential lumbar fusion with femoral ring allograft (FRA)
Number of subjects: 122
Study 26199198 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 547
Study 26199198 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 547
Study 26199198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Solifenacin
Number of subjects: 547
Study 26199198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 24754203 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG)
Number of subjects: 55
Study 24754203 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 55
Study 22411483 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 μg
Number of subjects: 10
Study 22411483 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 10
Study 22411483 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 150 μg and Midazolam 7.5 mg
Number of subjects: 10
Study 20973267 — intervention group
Group type: EXPERIMENTAL
Intervention: Canfosfamide + PLD (1000 mg/m² canfosfamide and 50 mg/m² PLD)
Number of subjects: 125
Study 20973267 — intervention group
Group type: COMPARATOR
Intervention: PLD alone (50 mg/m²)
Number of subjects: 125
Study 20973267 — intervention group
Group type: EXPERIMENTAL
Intervention: Canfosfamide + PLD
Number of subjects: 125
Study 20973267 — intervention group
Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 125
Study 18926983 — intervention group
Group type: EXPERIMENTAL
Intervention: Describing their actions in detail
Number of subjects: 2
Study 18926983 — intervention group
Group type: COMPARATOR
Intervention: Performing an irrelevant verbal task
Number of subjects: 2
Study 15809515 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hydrocortisone treatment (40 mg daily for 1 week)
Number of subjects: 19
Study 15809515 — intervention group
Group type: COMPARATOR
Intervention: Acute hydrocortisone treatment (40 mg)
Number of subjects: 19
Study 15809515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11435251 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) at various levels (5, 10, 15, 20 cm H2O) and tidal volume (VT) with plateau pressures of 10, 15, 20, 30, 35, and 45 cm H2O.
Number of subjects: 5
Study 9550542 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 138
Study 9550542 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 138
Study 8001714 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical records
Number of subjects: 2917
Study 8001714 — intervention group
Group type: EXPERIMENTAL
Intervention: USL registers
Number of subjects: 2917
Study 8001714 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions
Number of subjects: 2917
Study 8001714 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sources
Number of subjects: 2917
Study 8001714 — intervention group
Group type: COMPARATOR
Intervention: Family doctors' conclusions
Number of subjects: 2917
Study 2839382 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-soluble contrast medium
Number of subjects: 175
Study 2839382 — intervention group
Group type: COMPARATOR
Intervention: Aqueous contrast medium
Number of subjects: 175
Study 8512477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone sodium succinate (250 mg every 6 hours for 3 days) followed by oral prednisone (1 mg/kg per day for 11 days)
Number of subjects: 457
Study 8512477 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg per day for 14 days)
Number of subjects: 457
Study 8512477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral for 14 days)
Number of subjects: 457
Study 677577 — intervention group
Group type: EXPERIMENTAL
Intervention: Phleborheography
Number of subjects: 75
Study 31106353 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of systemic, pathogen-targeted antibiotic therapy
Number of subjects: 123
Study 31106353 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks of systemic, pathogen-targeted antibiotic therapy
Number of subjects: 123
Study 28277112 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g MYO and 400μg folic acid before and during ovulation induction (Group 1)
Number of subjects: 196
Study 28277112 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH and 400μg folic acid (Group 2)
Number of subjects: 196
Study 26267623 — intervention group
Group type: EXPERIMENTAL
Intervention: Open monitoring with fetal ST-segment analysis
Number of subjects: 11108
Study 26267623 — intervention group
Group type: COMPARATOR
Intervention: Masked monitoring (normal fetal heart-rate monitor)
Number of subjects: 11108
Study 24009749 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lutein supplement
Number of subjects: 72
Study 24009749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 21114552 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly e-mail messages and monthly personal e-mail messages with reporting of weight (n = 28)
Number of subjects: 55
Study 21114552 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 27)
Number of subjects: 55
Study 19017419 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng (G115)
Number of subjects: 29
Study 19017419 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng (Cheong Kwan Jang)
Number of subjects: 29
Study 17259481 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 217
Study 17259481 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 217
Study 15234035 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus cisplatin
Number of subjects: 101
Study 15234035 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus carboplatin
Number of subjects: 101
Study 15234035 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 101
Study 15234035 — intervention group
Group type: EXPERIMENTAL
Intervention: TGTV <22.8 cm(3)
Number of subjects: 101
Study 15234035 — intervention group
Group type: EXPERIMENTAL
Intervention: TGTV >22.8 cm(3)
Number of subjects: 101
Study 11412291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg(‐1)
Number of subjects: 60
Study 11412291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3.0 mg kg(‐1)
Number of subjects: 60
Study 11412291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3.5 mg kg(‐1)
Number of subjects: 60
Study 11412291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3.0 microg kg(‐1)
Number of subjects: 60
Study 9764960 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation I
Number of subjects: 18
Study 9764960 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation II
Number of subjects: 18
Study 9764960 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation III
Number of subjects: 18
Study 9764960 — intervention group
Group type: COMPARATOR
Intervention: Reference capsule
Number of subjects: 18
Study 8001064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42% F gel once a day for 1 year
Number of subjects: 55
Study 8001064 — intervention group
Group type: COMPARATOR
Intervention: 1.23% F gel for 4 weeks followed by 0.42% F gel daily for 1 year
Number of subjects: 55
Study 8001064 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstimulated saliva flow < 0.1 ml/min
Number of subjects: 55
Study 8001064 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated salivary flow < 0.5 ml/min
Number of subjects: 55
Study 8001064 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstimulated saliva flow > 0.1 ml/min with 0.42% F gel
Number of subjects: 55
Study 3356120 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg administered after a fast (Treatment A)
Number of subjects: 12
Study 3356120 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg with a standardized high-fat meal (Treatment B)
Number of subjects: 12
Study 3356120 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg with a standardized high-carbohydrate meal (Treatment C)
Number of subjects: 12
Study 3356120 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg after pretreatment with glutamic acid hydrochloride 680 mg (Treatment D)
Number of subjects: 12
Study 3356120 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg in a simulated achlorhydric state (Treatment E)
Number of subjects: 12
Study 3356120 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg with glutamic acid hydrochloride in a simulated achlorhydric state (Treatment F)
Number of subjects: 12
Study 29703518 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) population
Number of subjects: 7500
Study 29703518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulated patients
Number of subjects: 7500
Study 29229052 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation (TM)
Number of subjects: 24
Study 29229052 — intervention group
Group type: COMPARATOR
Intervention: Sham Manipulation (SM)
Number of subjects: 24
Study 25956366 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic vaginoplasty using a single peritoneal flap (SPF)
Number of subjects: 83
Study 25956366 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 83
Study 23249605 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session EUS-ERCP (group A)
Number of subjects: 180
Study 23249605 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS and ERCP in different sessions (group B)
Number of subjects: 180
Study 23249605 — intervention group
Group type: COMPARATOR
Intervention: ERCP-only procedure (group C)
Number of subjects: 180
Study 23249605 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 180
Study 21452051 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeWindows intervention
Number of subjects: 594
Study 21452051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 594
Study 19195133 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 0
Study 19195133 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency extracorporeal shock wave lithotripsy service
Number of subjects: 0
Study 17333040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Number of subjects: 59
Study 17333040 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy
Number of subjects: 59
Study 14769704 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin therapy for 30 days
Number of subjects: 272
Study 14769704 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic therapy (control group)
Number of subjects: 272
Study 14769704 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Roxithromycin and control)
Number of subjects: 272
Study 11290877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanepitant 50 mg daily
Number of subjects: 93
Study 11290877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanepitant 100 mg daily
Number of subjects: 93
Study 11290877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanepitant 200 mg twice daily
Number of subjects: 93
Study 11290877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 9716766 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 60
Study 9716766 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 60
Study 7803735 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium (DOX) 80 micrograms/kg
Number of subjects: 75
Study 7803735 — intervention group
Group type: COMPARATOR
Intervention: High-dose vecuronium (VEC) 400 micrograms/kg
Number of subjects: 75
Study 7803735 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium (DOX) in DOX-70 group
Number of subjects: 75
Study 7803735 — intervention group
Group type: COMPARATOR
Intervention: High-dose vecuronium (VEC)
Number of subjects: 75
Study 7803735 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium (DOX) and High-dose vecuronium (VEC)
Number of subjects: 75
Study 2904371 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sublingual tablet formulation of temazepam
Number of subjects: 10
Study 2904371 — intervention group
Group type: COMPARATOR
Intervention: 10 mg oral capsule formulation of temazepam
Number of subjects: 10
Study 31641948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fong's clinical risk score (CRS) as a categorical variable (CRS 0-1 vs. 2-3 vs. 4-5)
Number of subjects: 181
Study 31641948 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphonuclear neutrophil (PMN) count (> 6000/mm3 vs. ≤ 6000/mm3) before chemotherapy
Number of subjects: 181
Study 31641948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fong's clinical risk score (CRS)
Number of subjects: 181
Study 31641948 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-based chemotherapy regimen
Number of subjects: 181
Study 30472022 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal telemonitoring for 6 months
Number of subjects: 306
Study 30472022 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 26922634 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with drinking tap water using a Monoject® Curved 412 Tip Syringe
Number of subjects: 280
Study 26922634 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative instructions without irrigation
Number of subjects: 280
Study 25495134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg and famotidine 26.6 mg
Number of subjects: 86
Study 22707006 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 280
Study 22707006 — intervention group
Group type: COMPARATOR
Intervention: TVT Secur
Number of subjects: 280
Study 21720594 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented retrograde intramedullary (IM) nail fixation
Number of subjects: 20
Study 21720594 — intervention group
Group type: COMPARATOR
Intervention: Augmented periarticular locking‐plate fixation
Number of subjects: 20
Study 19690792 — intervention group
Group type: EXPERIMENTAL
Intervention: Group pelvic floor muscle training (PFMT)
Number of subjects: 60